Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.

By Z. Younossi, V. Ratziu, R. Loomba, M. Rinella, Q. Anstee, Z. Goodman, P. Bedossa, A. Geier, S. Beckebaum, P. Newsome and 25 more. The Lancet, 2019

1,024 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease (2020, background): “Over the 18-month trial duration, cholelithiasis or cholecystitis was observed in 3% (n = 19) of patients in the 25-mg group, 1% (n = 7) in the 10-mg group, and < 1% (n = 2) in the placebo group [277].”